Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has reported results of a study showing that its psychotropic medication Seroquel is an effective one-therapy treatment for manic and depressive episodes in patients with bipolar I and II disorders.
Subscribe to our email newsletter
According to the company, patients receiving Seroquel showed a statistically significant decrease in depression scores compared to patients taking placebo throughout the eight-week study. About 58% of the patients responded to the treatment and 52.9& achieved remission.
The results open up doors in the treatment of bipolar disorder, which affects more than 7 million US adults every year. The disorder is currently treated by multiple medications designed to manage the depressive and manic states.
Patients with bipolar disorder are symptomatic for almost half of their lives. They spend two-thirds of that time in the depressed phase of the illness, and suffer prolonged periods of sadness, unexplained loss of energy, persistent lethargy and recurring thoughts of death or suicide.
Seroquel is currently approved for the treatment of acute manic episodes associated with bipolar I disorder and the treatment of schizophrenia.